Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Agios Pharmaceuticals, Inc. discovers and develops therapeutics in the field of cancer metabolism. The Company develops drugs focusing on glycolysis, fatty acid metabolism, and autophagy. Agios Pharmaceuticals operates in the United States.
Website: agios.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 121.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -308.5%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.59 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 46.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 48.2% higher than minimum and 48.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.5x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.4 mln (-0.016% of cap.)

Key Financials (Download financials)

Ticker: AGIO
Share price, USD:  (-0.3%)31.59
year average price 30.90  


year start price 43.65 2025-11-16

max close price 45.49 2025-11-18

min close price 22.34 2025-11-19

current price 31.59 2026-11-15
Common stocks: 59 809 651

Dividend Yield:  0.0%
EV / Sales: 7.6x
Margin (EBITDA LTM / Revenue): -308.5%
Fundamental value created in LTM:
Market Cap ($m): 1 889
Net Debt ($m): -907
EV (Enterprise Value): 982
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-14seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-26zacks.com

Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?

2025-12-24seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

2025-12-24seekingalpha.com

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

2025-12-24zacks.com

AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label

2025-12-23globenewswire.com

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

2025-11-20zacks.com

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

2025-11-19seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

2025-11-04seekingalpha.com

Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones

2025-10-30seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-10-30 09:57:01 2025-07-31 10:29:01 2025-02-13 09:26:58 2024-10-31 09:20:39 2024-08-01 09:49:09 2024-05-02 09:20:21 2024-02-15 10:33:02 2023-11-02 09:20:31 2023-08-03 09:20:06 2023-05-04 09:55:44 2023-02-23 10:35:30 2022-11-03 09:46:35 2022-02-24 11:34:06 2021-02-25 11:36:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 13M 12M 36M 9M 9M 8M 27M 7M 7M 6M 14M 4M 0 0
costOfRevenue 2M 3M 4M 783 000 3M 2M 10M 633 000 1M 554 000 2M 517 000 19M 19M
grossProfit 11M 9M 32M 8M 6M 6M 17M 7M 6M 5M 13M 3M -19M -19M
grossProfitRatio 0.87 0.762 0.913 0.642 0.759 0.914 0.835 0.901 0.853
researchAndDevelopmentExpenses 87M 91M 301M 72M 76M 67M 289M 82M 69M 67M 280M 65M 257M 211M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 41M 46M 157M 39M 36M 31M 120M 26M 30M 28M 122M 29M 121M 106M
otherExpenses 0 0 0 0 2M 2M 0 1M 2M 2M 0 0 -19M 0
operatingExpenses 128M 137M 458M 111M 111M 98M 409M 108M 99M 96M 402M 94M 360M 317M
costAndExpenses 130M 140M 462M 112M 114M 100M 418M 108M 100M 96M 403M 95M 378M 336M
interestIncome 13M 15M 48M 13M 8M 9M 33M 8M 8M 8M 13M 4M 836 000 7M
interestExpense 0 0 0 0 0 0 0 0 0 -10M 0 4M 0 18M
depreciationAndAmortization 1M 1M 6M 1M 2M 1M 7M 2M 2M 2M 9M -2M 19M 19M
ebitda -102M -111M -420M -103M -104M -91M -385M -101M -94M -91M -380M -94M -338M -311M
ebitdaratio -7.924 -8.893 -11.469 -12.098 -11.079 -13.637 -13.96 -16.155 -26.608
operatingIncome -117M -127M -426M -103M -106M -92M -391M -101M -94M -91M -389M -91M -378M -336M
operatingIncomeRatio -9.074 -10.201 -11.469 -12.283 -11.243 -13.637 -13.96 -16.155 -25.907
totalOtherIncomeExpensesNet 13M 15M 1 144M 1 104M 10M 11M 39M 1M 2M 10M 157M 9M 22M 7M
incomeBeforeTax -103M -112M 718M 1 001M -96M -82M -352M -91M -84M -81M -232M -82M -357M -329M
incomeBeforeTaxRatio -8.031 -8.994 111.673 -11.157 -9.958 -12.343 -12.486 -14.444 -23.25
incomeTaxExpense 0 0 44M 53M 0 1M 0 -10M -10M -10M 0 -9M 0 0
netIncome -103M -112M 674M 948M -96M -82M -352M -91M -84M -71M -232M -72M 1 605M -327M
netIncomeRatio -8.031 -8.994 105.747 -11.157 -9.958 -12.343 -12.486 -12.734 -20.593
eps -1.78 -1.93 11.86 16.65 -1.69 -1.45 -6.33 -1.64 -1.51 -1.29 -4.23 -1.32 -6.36 -4.74
epsdiluted -1.78 -1.93 16.22 -1.69 -1.45 -1.64 -1.51 -1.29 -1.32
weightedAverageShsOut 58M 58M 57M 57M 57M 56M 56M 56M 56M 55M 55M 55M 60M 69M
weightedAverageShsOutDil 58M 58M 58M 58M 57M 56M 56M 56M 56M 55M 55M 55M 60M 69M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 48M 33M 13M 836 000 -11M
ebit -426M -391M -389M -357M -329M
nonOperatingIncomeExcludingInterest 0 0 0 -22M -7M
netIncomeFromContinuingOperations 674M -352M -232M -357M -329M
netIncomeFromDiscontinuedOperations 0 0 0 1 961M 2M
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 1 989M 0
bottomLineNetIncome 674M -352M -232M -384M -327M
epsDiluted 11.64 -6.33 -4.23 -6.36 -4.74

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-10-30 09:57:01 2025-07-31 10:29:01 2025-02-13 09:26:58 2024-10-31 09:20:39 2024-08-01 09:49:09 2024-05-02 09:20:21 2024-02-15 10:33:02 2023-11-02 09:20:31 2023-08-03 09:20:06 2023-05-04 09:55:44 2023-02-23 10:35:30 2022-11-03 09:46:35 2022-02-24 11:34:06 2021-02-25 11:36:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 93M 81M 76M 254M 85M 119M 88M 64M 85M 104M 139M 122M 203M 127M
shortTermInvestments 860M 858M 817M 751M 485M 479M 689M 583M 618M 635M 644M 605M 817M 445M
cashAndShortTermInvestments 953M 939M 894M 1 005M 570M 598M 777M 872M 947M 1 011M 783M 728M 1 020M 573M
netReceivables 5M 5M 4M 3M 4M 3M 3M 1M 2M 2M 2M 6M 4M 0
inventory 32M 31M 28M 26M 24M 23M 19M 17M 16M 11M 8M 5M 0 0
otherCurrentAssets 43M 45M 40M 40M 35M 39M 35M 38M 37M 39M 39M 46M 0 64M
totalCurrentAssets 1 033M 1 019M 966M 1 074M 632M 664M 834M 704M 757M 792M 833M 785M 1 064M 637M
propertyPlantEquipmentNet 44M 47M 55M 58M 61M 66M 70M 74M 80M 84M 88M 93M 104M 116M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 304M 400M 638M 656M 75M 116M 29M 225M 244M 272M 314M 298M 266M 98M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 4M 4M 5M 4M 4M 4M 4M 4M 4M 4M 4M 4M 3M 3M
totalNonCurrentAssets 353M 452M 698M 718M 141M 186M 103M 303M 328M 360M 406M 395M 374M 216M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 386M 1 471M 1 663M 1 792M 773M 850M 937M 1 007M 1 085M 1 151M 1 239M 1 180M 1 438M 853M
accountPayables 20M 18M 17M 17M 10M 11M 10M 13M 12M 9M 19M 10M 17M 18M
shortTermDebt 18M 18M 0 16M 32M 15M 0 15M 14M 14M 0 13M 0 7M
taxPayables 0 0 871 000 53M 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 37M 35M 47M 33M 21M 25M 23M 30M 29M 22M 12M 30M 20M 49M
totalCurrentLiabilities 75M 70M 81M 119M 63M 52M 68M 58M 55M 45M 63M 54M 60M 94M
longTermDebt 27M 31M 0 45M 98M 53M 0 61M 65M 68M 0 75M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 101 000 880 000 1M -48M 1M 1M 1M 1M 1M 3M 53M 0 261M
totalNonCurrentLiabilities 27M 31M 41M 46M 50M 54M 58M 62M 66M 70M 75M 77M 86M 359M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 27M 49M 57M 61M 65M 53M 72M 75M 79M 82M 86M 89M 97M 98M
totalLiabilities 101M 102M 122M 165M 113M 106M 126M 120M 121M 115M 138M 130M 146M 453M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 74 000 74 000 73 000 73 000 73 000 73 000 72 000 72 000 72 000 72 000 71 000 71 000 71 000 69 000
retainedEarnings -454M -350M -149M -52M -1 000M -904M -823M -727M -635M -552M -471M -507M -239M -1 843M
accumulatedOtherComprehensiveIncomeLoss 2M 655 000 -2M 3M -1M -1M -441 000 -6M -9M -8M -13M -15M -1M 105 000
othertotalStockholdersEquity 1 736M 1 719M 1 676M 1 662M 1 649M 1 619M 1 608M 1 596M 1 572M
totalStockholdersEquity 1 284M 1 370M 1 541M 1 627M 661M 744M 811M 887M 964M 1 037M 1 101M 1 050M 1 292M 400M
totalEquity 1 284M 1 370M 1 541M 1 627M 661M 744M 811M 887M 964M 1 037M 1 101M 1 050M 1 292M 400M
totalLiabilitiesAndStockholdersEquity 1 386M 1 471M 1 792M 773M 850M 1 007M 1 085M 1 151M 1 180M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 386M 1 471M 1 663M 1 792M 773M 850M 937M 1 007M 1 085M 1 151M 1 239M 1 180M 1 438M 853M
totalInvestments 1 164M 1 259M 1 456M 1 407M 561M 596M 718M 583M 618M 635M 958M 904M 1 083M 543M
totalDebt 45M 49M 57M 61M 65M 68M 72M 75M 79M 82M 86M 89M 97M 105M
netDebt -48M -32M -19M -193M -20M -50M -16M 11M -6M -22M -54M -34M -106M -22M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 4M 3M 2M 0 23M
otherReceivables 0 0 0 4M -23M
prepaids 0 0 0 40M 0
totalPayables 18M 10M 19M 17M 18M
otherPayables 871 000 0 0 0 0
accruedExpenses 0 20M 18M 12M 20M
capitalLeaseObligationsCurrent 17M 15M 14M 11M 0
capitalLeaseObligationsNonCurrent 40M 57M 72M 86M 98M
treasuryStock -802M -802M -802M -802M 0
additionalPaidInCapital 2 494M 2 437M 2 386M 2 334M 2 243M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO AGIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-10-30 09:57:01 2025-07-31 10:29:01 2025-02-13 09:26:58 2024-10-31 09:20:39 2024-08-01 09:49:09 2024-05-02 09:20:21 2024-02-15 10:33:02 2023-11-02 09:20:31 2023-08-03 09:20:06 2023-05-04 09:55:44 2023-02-23 10:35:30 2022-11-03 09:46:35 2022-02-24 11:34:06 2021-02-25 11:36:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -103M -112M 674M 948M -96M -82M -352M -91M -84M -81M -232M -82M -357M -329M
depreciationAndAmortization 1M 1M 6M 1M 2M 1M 7M 2M 2M 2M 9M 2M 9M 19M
deferredIncomeTax 0 0 0 0 0 0 0 1M -3M 0 0 0 0 0
stockBasedCompensation 12M 15M 43M 11M 12M 9M 45M 9M 12M 10M 49M 11M 54M 0
changeInWorkingCapital -231 000 8M -20M 19M 10M -29M -19M -3M 4M -26M -16M -5M -37M 2M
accountsReceivables -43 000 -2M -1M 644 000 -309 000 -643 000 -604 000 1M -473 000 428 000 -2M -220 000 -4M 0
inventory -1M -1M -9M -2M -867 000 -4M -11M -2M -4M -3M -8M -1M 0 -7M
accountsPayables 2M 4M 7M 7M -1M 1M -9M 2M 3M -10M 3M 3M 2M 3M
otherWorkingCapital -809 000 7M -17M 14M 12M -26M 864 000 -4M 6M 12M -9M -6M -34M 6M
otherNonCashItems 2M 11M -1 092M -1 063M 17M 15M 24M 20M 3M -318 000 -119M 2M -77M 18M
netCashProvidedByOperatingActivities -88M -77M -390M -84M -73M -100M -296M -62M -67M -95M -309M -71M -407M -291M
investmentsInPropertyPlantAndEquipment -2M -875 000 -2M -419 000 -158 000 -141 000 -999 000 -18M 3000 -399 000 -5M -38 000 -6M -14M
acquisitionsNet 0 0 40 000 -40 000 0 40 000 0 18M 0 0 133M 0 0 0
purchasesOfInvestments -175M -131M -1 542M -996M -105M -244M -418M -95M -104M -128M -1 031M -174M -1 378M -557M
salesMaturitiesOfInvestments 272M 221M 818M 158M 142M 369M 675M 151M 151M 186M 1 146M 279M 830M 648M
otherInvestingActivites 0 -10M 1 089M 37M 40 000 -16M 0 150 000 0
netCashUsedForInvestingActivites 96M 79M 251M 37M 125M 39M 47M 58M 104M
debtRepayment 0 0 0 0 0 0 0 0 -84 000
commonStockIssued 4M 65 000 3M 1M 6M 2M 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 -802M 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 3M 1M 6M 0 0 2M 1M
netCashUsedProvidedByFinancingActivities 4M 65 000 3M 1M 6M 2M 237 000 2M 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 31M 0 0 0 0 1
netChangeInCash 12M 2M -12M 169M -34M 31M -51M -20M -19M -35M -64M 34M 76M 47M
cashAtEndOfPeriod 93M 81M 76M 254M 85M 119M 88M 64M 85M 104M 139M 122M 203M 127M
cashAtBeginningOfPeriod 81M 79M 88M 85M 119M 88M 139M 85M 104M 139M 203M 89M 127M 81M
operatingCashFlow -88M -77M -390M -84M -73M -100M -296M -62M -67M -95M -309M -71M -407M -291M
capitalExpenditure -2M -875 000 -2M -419 000 -158 000 -141 000 -999 000 -18M 3000 -399 000 -5M -38 000 -6M -14M
freeCashFlow -90M -78M -392M -85M -73M -100M -297M -80M -67M -96M -314M -71M -413M -305M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 1 089M -16M 0 1 803M -803 000
netCashProvidedByInvestingActivities 363M 240M 243M 1 249M 76M
netDebtIssuance 0 0 -331 000 -578 000 -336 000
longTermNetDebtIssuance 0 0 -331 000 -578 000 -336 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 14M 5M 3M -802M 11M
netCommonStockIssuance 14M 5M 3M -802M 11M
commonStockIssuance 14M 5M 3M 0 11M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 37M 251M
netCashProvidedByFinancingActivities 14M 5M 2M -766M 262M
incomeTaxesPaid 43M 2M 0 16M 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-04 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-11-05 ET
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-04 ET
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
2026-10-30 ET
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
2026-10-20 ET
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
2026-10-08 ET
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
2026-07-30 ET
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-21 ET
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
2026-07-07 ET
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
2026-06-29 ET
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
2026-06-13 ET
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
2026-06-01 ET
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
2026-05-29 11:00 ET
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
2026-05-22 14:18 ET
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
2026-05-22 13:15 ET
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
2026-05-12 ET
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
2026-05-12 ET
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
2026-04-29 ET
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-06 ET
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
2026-03-31 ET
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
2026-03-02 ET
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
2026-02-12 11:30 ET
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-01-26 ET
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
2026-01-12 ET
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
2026-01-05 ET
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
2025-12-23 ET
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
2025-12-08 ET
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
2025-11-19 ET
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
2025-11-03 ET
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
2025-10-30 10:30 ET
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-10-17 ET
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia
2025-10-17 ET
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
2025-10-16 ET
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
2025-09-04 ET
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
2025-08-04 ET
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
2025-07-31 ET
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-14 ET
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
2025-07-08 ET
Agios Appoints Dr. Jay Backstrom to Board of Directors
2025-06-09 ET
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders
2025-05-28 ET
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
2025-05-14 ET
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
2025-05-09 ET
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
2025-05-02 ET
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
2025-05-01 ET
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
2025-04-17 ET
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
2025-03-05 ET
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
2025-03-04 ET
Agios to Present at Upcoming Investor Conferences
2025-02-20 ET
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
2025-02-13 ET
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
2025-02-13 ET
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
2025-02-06 ET
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
2025-01-13 ET
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
2025-01-08 ET
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
2025-01-08 ET
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
2025-01-03 ET
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
2024-12-18 ET
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
2024-12-08 ET
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
2024-11-05 ET
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
2024-10-23 11:00 ET
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
2024-10-17 11:00 ET
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
2024-09-11 11:00 ET
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
2024-09-05 11:00 ET
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
2024-08-01 10:31 ET
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
2024-08-01 10:30 ET
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
2024-07-18 11:00 ET
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
2024-06-15 12:45 ET
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
2024-06-06 13:00 ET
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
2024-06-03 10:30 ET
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
2024-05-30 20:05 ET
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
2024-05-28 11:00 ET
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
2024-05-14 14:00 ET
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
2024-05-06 11:00 ET
Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
2024-05-03 11:00 ET
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
2024-05-02 11:00 ET
Agios Reports Business Highlights and First Quarter 2024 Financial Results
2024-04-18 11:00 ET
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
2024-04-09 11:00 ET
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
2024-03-05 12:00 ET
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
2024-02-22 12:00 ET
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
2024-02-15 12:00 ET
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2024-02-02 12:00 ET
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
2024-01-08 12:00 ET
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
2024-01-03 11:30 ET
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
2024-01-02 12:00 ET
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
2023-12-10 00:00 ET
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
2023-11-20 12:00 ET
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
2023-11-02 13:05 ET
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
2023-11-02 11:00 ET
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
2023-10-19 11:00 ET
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
2023-08-29 11:00 ET
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
2023-08-03 10:35 ET
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
2023-08-03 10:30 ET
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
2023-07-13 11:00 ET
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
2023-06-26 10:30 ET
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
2023-06-05 11:00 ET
Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023
2023-05-25 11:00 ET
Agios Appoints Catherine Owen to Board of Directors
2023-05-11 14:00 ET
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
2023-05-04 11:00 ET
Agios Reports Business Highlights and First Quarter 2023 Financial Results
2023-04-25 11:00 ET
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
2023-04-19 11:00 ET
Agios Appoints Jeffrey Capello to Board of Directors
2023-04-13 11:00 ET
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
2023-04-12 12:00 ET
Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero
2023-04-03 11:00 ET
Agios Publishes 2023 Environmental, Social and Governance (ESG) Report
2023-03-02 13:26 ET
Agios to Participate in March Investor Conferences
2023-02-28 12:00 ET
Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day
2023-02-23 12:00 ET
Agios Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-02 12:00 ET
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
2023-01-09 01:00 ET
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases
2023-01-03 22:57 ET
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
2022-12-21 13:00 ET
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
2022-12-12 00:00 ET
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
2022-12-10 23:30 ET
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual ...
2022-12-06 12:00 ET
Agios Appoints Tsveta Milanova as Chief Commercial Officer
2022-11-30 13:00 ET
Agios to Participate in December Investor Conference
2022-11-10 21:01 ET
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
2022-11-03 13:00 ET
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
2022-11-03 11:00 ET
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
2022-10-27 20:01 ET
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
2022-10-27 ET
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
2022-10-20 11:00 ET
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
2022-09-26 23:13 ET
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
2022-09-19 11:00 ET
Agios Appoints Cecilia Jones as Chief Financial Officer
2022-09-16 10:41 ET
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
2022-08-24 11:00 ET
Agios to Participate in September Investor Conferences
2022-08-18 22:35 ET
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
2022-08-15 12:00 ET
Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
2022-08-11 22:35 ET
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
2022-08-08 22:36 ET
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
2022-08-04 11:00 ET
Agios Reports Business Highlights and Second Quarter 2022 Financial Results
2022-07-14 11:00 ET
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
2022-07-12 20:01 ET
Agios Appoints Brian Goff as Chief Executive Officer
2022-06-10 14:30 ET
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
2022-05-16 20:15 ET
Agios Announces Evolution of Research Organization
2022-05-12 14:00 ET
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
2022-05-10 11:00 ET
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
2022-05-05 11:00 ET
Agios Reports Business Highlights and First Quarter 2022 Financial Results
2022-04-21 11:00 ET
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
2022-04-14 12:34 ET
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
2022-02-28 12:00 ET
Agios to Participate in March Investor Conferences
2022-02-24 12:00 ET
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-17 20:41 ET
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
2022-02-10 12:00 ET
Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022
2022-01-10 12:00 ET
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
2021-12-22 12:00 ET
Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
2021-12-13 23:15 ET
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
2021-12-13 15:30 ET
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
2021-12-13 12:00 ET
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition
2021-11-15 21:01 ET
Agios Appoints Richa Poddar as Chief Commercial Officer
2021-11-04 13:00 ET
Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition
2021-11-03 11:10 ET
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
2021-10-21 20:01 ET
Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
2021-08-30 11:00 ET
Agios To Present at September Investor Conferences
2021-08-17 20:01 ET
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
2021-07-29 11:00 ET
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
2021-07-15 11:00 ET
Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021
2021-06-28 11:00 ET
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
2021-06-22 11:00 ET
Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency
2021-06-21 11:00 ET
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
2021-06-11 07:00 ET
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
2021-06-11 07:00 ET
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
2021-05-12 14:00 ET
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress
2021-04-29 11:00 ET
Agios Reports Business Highlights and First Quarter 2021 Financial Results
2021-04-15 11:00 ET
Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
2021-04-01 11:00 ET
Agios Announces Closing of Oncology Business Sale to Servier
2021-03-25 20:01 ET
Agios Shareholders Approve Sale of Oncology Business to Servier
2021-03-18 11:00 ET
Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
2021-03-01 12:00 ET
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
2021-02-26 12:00 ET
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias
2021-02-25 12:00 ET
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-23 12:00 ET
Agios to Present at March Investor Conferences
2021-02-11 12:00 ET
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
2021-01-26 21:01 ET
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused
2021-01-17 15:00 ET
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
2021-01-11 12:00 ET
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
2021-01-05 12:00 ET
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
2020-12-21 12:00 ET
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
2020-12-07 21:30 ET
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
2020-12-01 12:00 ET
Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
2020-11-30 12:00 ET
Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
2020-11-25 12:00 ET
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
2020-11-12 21:30 ET
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
2020-11-05 12:00 ET
Agios Reports Business Highlights and Third Quarter 2020 Financial Results
2020-11-04 16:46 ET
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
2020-10-29 20:01 ET
Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020
2020-10-22 11:00 ET
Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020
2020-10-16 20:01 ET
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
2020-09-21 11:00 ET
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
2020-09-08 20:01 ET
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs
2020-08-27 11:00 ET
Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020
2020-08-06 11:00 ET
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
2020-07-30 11:00 ET
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
2020-07-16 11:01 ET
Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020
2020-06-17 20:01 ET
Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020
2020-06-12 10:30 ET
Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty
2020-06-12 06:30 ET
Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study
2020-06-12 06:30 ET
Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease
2020-06-08 20:01 ET
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia
2020-05-29 12:00 ET
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma
2020-05-19 11:00 ET
Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
2020-05-14 13:41 ET
Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress
2020-05-13 21:01 ET
Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting
2020-05-12 11:00 ET
Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020
2020-04-30 11:00 ET
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response
2020-04-16 11:00 ET
Agios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020
2020-03-30 20:01 ET
Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase Deficiency
2020-03-25 20:01 ET
Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb
2020-03-23 11:00 ET
Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR Activator
2020-02-18 12:00 ET
Agios to Present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020
2020-02-13 12:00 ET
Agios Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-11 12:00 ET
Agios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020
2020-01-30 12:00 ET
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020
2020-01-12 21:00 ET
Agios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones
2019-12-23 12:00 ET
Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020
2019-12-16 21:00 ET
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2019-12-09 15:00 ET
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
2019-12-09 13:00 ET
Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
2019-12-08 14:00 ET
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
2019-12-02 12:00 ET
Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer
2019-11-25 12:00 ET
Agios Appoints Jonathan Biller as Chief Legal Officer
2019-11-22 21:00 ET
Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma
2019-11-13 15:21 ET
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
2019-11-08 02:17 ET
Agios Announces Pricing of $256 Million Public Offering of Common Stock
2019-11-06 21:01 ET
Agios Announces Proposed Offering of Common Stock
2019-11-06 14:28 ET
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting
2019-10-31 11:00 ET
Agios Reports Business Highlights and Third Quarter 2019 Financial Results
2019-10-27 15:50 ET
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors
2019-10-17 11:00 ET
Agios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019
2019-10-09 11:00 ET
Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference
2019-09-30 14:30 ET
Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients
2019-09-10 11:00 ET
Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO
2019-04-02 20:00 ET
Agios Announces New Commercial Leadership Structure
2019-03-26 20:00 ET
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy
2019-03-04 12:00 ET
Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019

SEC forms

Show financial reports only

SEC form 8
2026-11-05 00:00 ET
Agios Pharmaceuticals reported for 2026 q3
SEC form 8
2026-11-05 00:00 ET
Agios Pharmaceuticals published news for 2026 q3
SEC form 10
2026-11-05 00:00 ET
Agios Pharmaceuticals reported for 2026 q3
SEC form 10
2026-07-30 13:56 ET
Agios Pharmaceuticals reported for 2026 q2
SEC form 8
2026-07-30 10:32 ET
Agios Pharmaceuticals published news for 2026 q2
SEC form 8
2026-07-30 10:32 ET
Agios Pharmaceuticals reported for 2026 q2
SEC form 10
2026-04-29 13:22 ET
Agios Pharmaceuticals reported for 2026 q1
SEC form 8
2026-04-29 10:32 ET
Agios Pharmaceuticals published news for 2026 q1
SEC form 8
2026-04-29 10:32 ET
Agios Pharmaceuticals reported for 2026 q1
SEC form 10
2026-02-12 09:33 ET
Agios Pharmaceuticals reported for 2025 q4
SEC form 8
2026-02-12 06:32 ET
Agios Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-12 06:32 ET
Agios Pharmaceuticals reported for 2025 q4
SEC form 8
2026-01-12 12:11 ET
Agios Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-12 12:11 ET
Agios Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-12 12:11 ET
Agios Pharmaceuticals published news for 2025 q4
SEC form 10
2025-10-30 13:57 ET
Agios Pharmaceuticals reported for 2025 q3
SEC form 8
2025-10-30 10:32 ET
Agios Pharmaceuticals reported for 2025 q3
SEC form 8
2025-10-30 10:32 ET
Agios Pharmaceuticals published news for 2025 q3
SEC form 10
2025-07-31 14:29 ET
Agios Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-31 10:38 ET
Agios Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-31 10:38 ET
Agios Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-01 14:26 ET
Agios Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-01 10:32 ET
Agios Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-01 10:32 ET
Agios Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Agios Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-13 09:26 ET
Agios Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-13 06:32 ET
Agios Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-13 06:32 ET
Agios Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
Agios Pharmaceuticals reported for 2024 q4
SEC form 10
2024-10-31 09:20 ET
Agios Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-31 06:56 ET
Agios Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-31 06:56 ET
Agios Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 09:49 ET
Agios Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-01 07:03 ET
Agios Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-01 07:03 ET
Agios Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Agios Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-02 09:20 ET
Agios Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-02 07:01 ET
Agios Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-02 07:01 ET
Agios Pharmaceuticals published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Agios Pharmaceuticals published news for 2024 q1
SEC form 8
2024-02-15 00:00 ET
Agios Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Agios Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-15 00:00 ET
Agios Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-02 09:20 ET
Agios Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-02 07:02 ET
Agios Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Agios Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-03 09:20 ET
Agios Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-03 06:38 ET
Agios Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Agios Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Agios Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-15 16:17 ET
Agios Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-15 16:13 ET
Agios Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-14 16:05 ET
Agios Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Agios Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Agios Pharmaceuticals published news for 2023 q1
SEC form 8
2023-02-23 00:00 ET
Agios Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Agios Pharmaceuticals reported for 2022 q4
SEC form 10
2022-11-03 00:00 ET
Agios Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Agios Pharmaceuticals reported for 2022 q3
SEC form 8
2022-08-04 00:00 ET
Agios Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Agios Pharmaceuticals reported for 2022 q2
SEC form 8
2022-05-05 00:00 ET
Agios Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Agios Pharmaceuticals reported for 2022 q1
SEC form 8
2022-02-24 00:00 ET
Agios Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Agios Pharmaceuticals published news for 2021 q4
SEC form 8
2021-11-03 00:00 ET
Agios Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Agios Pharmaceuticals published news for 2021 q3
SEC form 8
2021-07-29 00:00 ET
Agios Pharmaceuticals published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Agios Pharmaceuticals published news for 2021 q2
SEC form 8
2021-04-29 00:00 ET
Agios Pharmaceuticals published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
Agios Pharmaceuticals published news for 2021 q1